Skip to content

Study · Non-randomized trial · n = 46 · 1995

4 results

Leuprolide acetate treatment and myoma arterial size.

Rutgers JL, Spong CY, Sinow R, Heiner J

Obstetrics and gynecology1 Sept 1995Cited by 40 (Europe PMC)

PMID7651647 (opens in a new tab)DOI10.1016/0029-7844(95)00191-s (opens in a new tab)PepBankPUB-07651647
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with myomas, intramyomatous arteries were 24% smaller with leuprolide than placebo (136 +/- 42 versus 178 +/- 60 microns, P < .01).

    In plain wordsArteries inside myomas were 24% smaller with leuprolide than placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseIntramyomatous arterial diameter
    Study

    n = 46

    Comparator
    Placebo
    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    3.75 or 7.5 mg in three monthly dosesAs given in this study (human).

    Measurements

    Diameter reduction
    24%
    versus placebo
    Arterial diameter
    136 microns
    leuprolide
    Arterial diameter
    178 microns
    placebo

    Source sentences

    Summary
    The average diameter of intramyomatous arteries was 24% smaller in GnRH-a subjects compared with those receiving placebo (136 +/- 42 versus 178 +/- 60 microns, P < .01).
    1 context sentence
    Summary · context
    Our study group included 46 women about to undergo myomectomy or hysterectomy; 30 were treated with leuprolide acetate (3.75 or 7.5 mg) in three monthly doses, and 16 were given placebo.
  2. 02HumanNon-randomized trialSafety outcome

    In women with myomas, arteriosclerotic changes occurred more often with leuprolide than placebo (48 versus 25%, P < .05).

    In plain wordsArteriosclerotic changes occurred more often with leuprolide than placebo.

    Peptide
    Leuprolide
    Outcome
    IncreaseArteriosclerotic changes
    Study

    n = 46

    Comparator
    Placebo
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    3.75 or 7.5 mg in three monthly dosesAs given in this study (human).

    Measurements

    Arteriosclerotic changes
    48%
    leuprolide
    Arteriosclerotic changes
    25%
    placebo

    Source sentences

    Summary
    In addition, arteriosclerotic changes, including intimal and medial fibrosis, were seen more often in the GnRH-a-treated subjects (48 versus 25%, P < .05).
    1 context sentence
    Summary · context
    Our study group included 46 women about to undergo myomectomy or hysterectomy; 30 were treated with leuprolide acetate (3.75 or 7.5 mg) in three monthly doses, and 16 were given placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with myomas, uterine volume decreased by an average of 30% during leuprolide treatment.

    In plain wordsUterine volume decreased by 30% in women receiving leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreaseUterine volume
    Study

    n = 30

    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    3.75 or 7.5 mg in three monthly dosesAs given in this study (human).

    Measurements

    Uterine volume decrease
    30%
    leuprolide

    Source sentences

    Summary
    Clinically and radiologically, the uterine volume of GnRH-a-treated patients decreased by an average of 30%, and the diameter of the largest myoma decreased by 27%.
    1 context sentence
    Summary · context
    Our study group included 46 women about to undergo myomectomy or hysterectomy; 30 were treated with leuprolide acetate (3.75 or 7.5 mg) in three monthly doses, and 16 were given placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with myomas, the largest myoma diameter decreased by 27% during leuprolide treatment.

    In plain wordsThe largest myoma diameter decreased by 27% in women receiving leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreaseLargest myoma diameter
    Study

    n = 30

    Outcome group
    Tumor growth · Reproductive and sexual health
    Studied dose
    3.75 or 7.5 mg in three monthly dosesAs given in this study (human).

    Measurements

    Largest myoma diameter decrease
    27%
    leuprolide

    Source sentences

    Summary
    Clinically and radiologically, the uterine volume of GnRH-a-treated patients decreased by an average of 30%, and the diameter of the largest myoma decreased by 27%.
    1 context sentence
    Summary · context
    Our study group included 46 women about to undergo myomectomy or hysterectomy; 30 were treated with leuprolide acetate (3.75 or 7.5 mg) in three monthly doses, and 16 were given placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.